Invention Grant
US07812162B2 Enantiomers of 2′-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics
有权
2'-氟烷基-6-硝基喹嗪作为血清素转运体正电子发射断层扫描成像剂和抗抑郁治疗剂的对映异构体
- Patent Title: Enantiomers of 2′-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics
- Patent Title (中): 2'-氟烷基-6-硝基喹嗪作为血清素转运体正电子发射断层扫描成像剂和抗抑郁治疗剂的对映异构体
-
Application No.: US11796227Application Date: 2007-04-26
-
Publication No.: US07812162B2Publication Date: 2010-10-12
- Inventor: John M. Gerdes , David B. Bolstad , Brian R. Kusche
- Applicant: John M. Gerdes , David B. Bolstad , Brian R. Kusche
- Applicant Address: US MT Missoula
- Assignee: The University of Montana
- Current Assignee: The University of Montana
- Current Assignee Address: US MT Missoula
- Agent Jean Kyle
- Main IPC: C07D401/04
- IPC: C07D401/04 ; A61K31/496 ; G01N33/53

Abstract:
Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radio-labelled 2′-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2′-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.
Public/Granted literature
Information query